The largest database of trusted experimental protocols

Cisplatin dichloride

Manufactured by Merck Group
Sourced in United States

Cisplatin dichloride is a platinum-based compound used as a laboratory reagent. It is a crystalline solid with the chemical formula PtCl2(NH3)2. This compound is commonly used in research applications, particularly in the fields of chemistry and biochemistry.

Automatically generated - may contain errors

2 protocols using cisplatin dichloride

1

Synthesis and Characterization of Multifunctional Nanoparticles

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gelatin (Bloom type-A; CAS No. 9000-70-8), Sodium tripolyphosphate (TPP; CAS No. 7758-29-4), Rhodamine-B (CAS No. 81-88-9), Cisplatin dichloride (CAS No. 15663-27-1), sodium borohydride (CAS No. 16940-66-2), dithiolated diethylenetriamine pentaacetic acid (DTDTPA), gold (III) chloride hydrate (CAS No. 27988-77-8) and glutaraldehyde (CAS No. 111-30-8) were purchased from Sigma-Aldrich (USA). Sterile ultraclean distilled water (Cat No. 10-977-015), sodium hydroxide (NaOH; CAS No. 1310-73-2), hydrochloric acid (HCl; CAS No. 7647-01-0), 200-proof ethanol (CAS No. 64-17-5), acetone (CAS No. 67-64-1), sodium chloride (NaCl; CAS No. 7647-14-5), sucrose (CAS No. 57-50-1), paraformaldehyde (PFA; Cat. No. 50-980-486), RPMI-media (Cat. No. A1049101) and fetal bovine serum (FBS; Cat. No. 26-140-079) were purchased from Thermo Fisher Scientific (USA). HS-PEG-OMe (Cat. No. 12750-40) was purchased from RAPP Polymere (Germany) and HS-PEG-COOH (Cat. No. CM-PEG–SH–2000) was purchased from Laysan Bio (USA). Doxorubicin (CAS No. 25316-40-9) was purchased from LC Laboratories (USA). Cy5 NHS ester (Cat. No. 23020) was purchased from Lumiprobe (USA). Iodixanol (Visipaque ®; Cat. No. 00407222317) was obtained from GE Healthcare (USA).
+ Open protocol
+ Expand
2

Cytotoxicity Assessment of Anticancer Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The cytotoxicity of various drugs in cells was assessed by seeding 3000 cells into each well of a 96-well plate, followed by incubation overnight and treatment with various concentrations of the drugs for 72 h. Cisplatin dichloride, mitoxantrone dichloride, raltitrexed, cytarabine and paclitaxel were purchased from Sigma; 5-FU was purchased from Fluka; docetaxel, gemcitabine and oxaliplatin were obtained from the USP; gefitinib and irinotecan were purchased from Caymann; and doxorubicin dihydrochloride was obtained from Pfizer. Cell growth was determined by the PrestoBlue (Invitrogen, Carlsbad, CA, USA) assay using a microplate spectrometer and fluorescence microplate spectrophotometer. By aid of CompuSyn software (version 1.0.1; CompuSyn, Inc., Paramus, NJ, USA), the IC50 value of each drug was calculated based on the median-effect principle and plotted using the dose–effect relationship at nine concentrations [69 (link)]. The same protocol and software were adopted to determine the combination index (CI) of the combination treatment.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!